4/A

PRIMARY DOCUMENT

Company: Ultragenyx Pharmaceutical Inc.
Filed: November 18, 2016
Period of Report: June 17, 2015
Accession Number: 0001562180-16-003577

View Document ↗ View on SEC.gov ↗